Omeros reports primate data for OncotoX-AML program
Apr 10, 2026
Omeros reported initial nonhuman primate data for OncotoX-AML in acute myeloid leukemia. One treatment course reduced myeloid progenitor cells by up to 99% and was well tolerated.
News Related to Azacitidine
Related coverage linked through entity extraction aliases.
Neuromyelitis Optica Spectrum Disorder Pipeline Shows 10+ Active Therapies in Development
Mar 05, 2026
Over 10 companies are developing 12+ pipeline therapies for Neuromyelitis Optica Spectrum Disorder, including Roche's satralizumab Phase III pediatric trial and multiple anti-CD20 monoclonal antibody candidates.
Faron's Bexmarilimab Data Accepted for BSH Presentation; New AML Study Launched
Feb 24, 2026
Faron Pharmaceuticals announces acceptance of bexmarilimab Phase I/II data for poster presentation at BSH 2026, while launching a new Phase II BEAM-X study evaluating the drug in AML patients post-stem cell transplantation.
Faron Initiates Phase II BEAM-X Trial for Post-Transplant AML Relapse Prevention
Feb 19, 2026
Faron Pharmaceuticals announces Phase II BEAM-X trial evaluating bexmarilimab plus azacitidine in MRD-positive AML patients after stem cell transplantation. The Nordic AML Group-led trial will enroll 24 patients with first results expected 12-15 months after enrollment begins in Q3 2026.